

Adjuvante Therapie und Rezidivrisiko des Nierenzellkarzinoms (S. 8–11)

N. Kröger, M. Burchardt

Literatur:

1. Robert Koch Institut. Zentrum für Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Schätzung der Inzidenz, Prävalenz und des Überlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten. 2021
2. Ljungberg B et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol* 2022
3. Chamie K et al. Adjuvant Weekly Girentuximab Following Nephrectomy for HighRisk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. *JAMA Oncol* 2017; 3: 913–20
4. Kroeger N et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. *Eur Urol* 2014; 65: 1086–92
5. Haas NB et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet* 2016; 387(10032): 2008–16
6. Motzer RJ et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol* 2021; 79: 334–8
7. Quinn DI et al. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. *ESMO Open* 2021; 6(3): 100105
8. Motzer RJ et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *Eur Urol* 2018; 73: 62–8
9. Ravaud A et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *N Engl J Med* 2016; 375: 2246–54
10. Choueiri TK et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. *J Clin Oncol* 2022; 40(6_suppl): 290
11. Klatte T et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 894–900
12. Rini B et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. *Lancet Oncol* 2015; 16: 676–85
13. Rini BI et al. Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. *Clin Cancer Res* 2018; 24: 4407–15
14. Kroeger N et al. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. *Eur J Cancer* 2022; 168: 68–76
15. Kroeger N et al. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *J Urol* 2012; 187: 418–23

16. Kroeger N et al. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. *Cancer* 2013; 119: 1547–54
 17. Bedke J et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. *BJU Int* 2018; 121: 84–92
 18. Kattan MW et al. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001; 166: 63–7
 19. Frank I et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. *J Urol* 2003; 170(6 Pt 1): 2225–32
 20. Sorbellini M et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. *J Urol* 2005; 173: 48–51
 21. Lam JS et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. *J Urol* 2005; 174: 466–72; discussion 72; quiz 801
-

CRP-Kinetik sagt das Immuntherapieansprechen beim metastasierten Nierenzell- und Urothelkarzinom voraus (S. 12–14)

N. Klümper, J. Saal, D. Sikic, M. Eckstein

Literatur:

1. Fukuda S et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. *J Immunother Cancer* 2021; 9
 2. Klümper N et al. C-reactive protein flare-response predicts long-term efficacy to firstline anti-PD-1-based combination therapy in metastatic renal cell carcinoma. *Clin Transl Immunology* 2021; 10: e1358
 3. Klümper N et al. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. *Eur J Cancer* 2022; 167: 13–22
 4. Klümper N et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. *J Immunother Cancer* 2022; 10: e004024
-

Aktuelle Aspekte zur Osteoprotektion bei Prostatakarzinompatienten (S. 15–18)

T. Steuber

Literatur:

1. Smith MR et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. *J Urol* 2006; 175: 136–9
2. Shahinian VB et al. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005 Jan 13; 352: 154–64

3. Smith MR et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009; 361: 745–55
4. Hupe MC et al. Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance. *Aktuelle Urol* 2022; 53: 43–53
5. Dachverband Osteologie (DVO) Leitlinie Osteoporose 2017, Kitteltaschenversion
6. University of Sheffield. FRAX® Fracture Risk Assessment Tool. (<https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9>) Zugegriffen: 16.09.2020
7. Coleman R et al. Bone health in cancer: ESMO Clinical Practice Guidelines. *Ann Oncol* 2020; 31: 1650–63
8. Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer *N Engl J Med* 2018; 378: 1408–18
9. Hussain M et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer *N Engl J Med* 2018; 378: 2465–74
10. Smith M et al. Addition of radium-223 to abirateroneacetate and prednisone or prednisolone in patients with castrationresistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 408–19
11. <https://clinicaltrials.gov/ct2/show/NCT02194842>
12. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatakarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.2.pdf
13. Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002; 94: 1458–68
14. Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. *Lancet* 2011; 377: 813–22
15. Smith MR et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). *J Clin Oncol* 2014; 32: 1143–50
16. Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371: 424–33

Systemtherapie des Urothelkarzinoms – eine Alternative zur Zystektomie? (19–23)

L. Yirga, S. Tschirdewahn, V. Grünwald

Literatur:

1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020, AWMF-Registrierungsnummer 032/038OL, 2020 [Available from: <https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/> (Letzter Aufruf: 29.04.2022)]
2. Stein JP et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001; 19(3): 666–75

3. Tyson MD II Barocas DA. Quality of Life After Radical Cystectomy. *Urol Clin North Am* 2018; 45(2): 249–256
4. Allareddy V et al. Quality of life in long-term survivors of bladder cancer. *Cancer* 2006; 106(11): 2355–62
5. Hassine BA et al. Quality of life in men after total cystoprostatectomy: Perceptions of Tunisian patients. *Can Oncol Nurs J* 2019; 29(4): 226–31
6. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol* 2005; 48(2): 202–5; discussion 205–6
7. Martini A et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. *Cancer* 2019; 125(18): 3155–63
8. Salminen AP et al. Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. *Bladder Cancer* 2019; 5: 273–9
9. Galsky MD et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J Clin Oncol* 2011; 29(17): 2432–8
10. Witjes A (Chair) et al. EAU Guidelines Muscle-invasive and Metastatic Bladder Cancer. Arnhem, The Netherlands.: EAU Guidelines Office; 2021
11. Ploussard G et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2014; 66(1): 120–37
12. Ploussard G et al. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol* 2014; 66(1): 120–37
13. Efstathiou JA et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. *Eur Urol* 2012; 61(4): 705–11
14. Dunst J et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. *Int J Radiat Oncol Biol Phys* 1994; 30(2): 261–6
15. Rosenblatt R et al. Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. *Eur Urol* 2012; 61(6): 1229–38
16. Powles T et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2020; 383(13): 1218–30
17. Bellmunt J et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med* 2017; 376(11): 1015–26
18. Fradet Y et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. *Ann Oncol* 2019; 30(6): 970–6
19. Necchi A et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol* 2018; 36(34): 3353–60
20. Powles T et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nat Med* 2019; 25(11): 1706–14
21. Cathomas R et al. Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC):

- Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17). *J Clin Oncol* 2020; 38(6_suppl): 499
22. Grande E et al. DUTRENEO Trial: A randomized phase II trial of DURvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. *J Clin Oncol* 2020; 38(15_suppl): 5012
 23. Schulz GB, Black PC. Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review. *Transl Androl Urol* 2021; 10(10): 4014–21
 24. van Dijk N et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. *Nat Med* 2020; 26(12): 1839–44
 25. Gupta S et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. *J Clin Oncol* 2020; 38(6_suppl): 439
 26. Hoimes CJ et al. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. *J Clin Oncol* 2020; 38(15_suppl): 5047
 27. Kaimakliotis HZ et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. *J Clin Oncol* 2020; 38(15_suppl): 5019
 28. Powles T et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N Engl J Med* 2021; 384(12): 1125–35
 29. Petrylak DP et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. *J Clin Oncol* 2022; 40(6_suppl): 435
 30. Muro XGd et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial. *J Clin Oncol* 2021; 39(15_suppl): 4505
 31. Balar AV et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial. *J Clin Oncol* 2021; 39(15_suppl): 4504
 32. Galsky MD et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257. *J Clin Oncol* 2021; 39(15_suppl): 4503
 33. van Hattum JW et al Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review. *Cancers (Basel)* 2021; 14(1): 38
 34. Dash A et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. *Cancer* 2008; 113(9): 2471–7
 35. Gandhi NM et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. *Urol Oncol* 2015; 33(5): 204.e1–.e2047
 36. Necchi A et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *Eur Urol* 2020; 77(4): 439–46

37. Weickhardt AJ et al. Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). *J Clin Oncol* 2020; 38(6_suppl): 485
-

Neue Therapieansätze beim Blasenkarzinom (S. 24–30)

E. Hellmis

Literatur:

1. Globocan 2020 Cancer Fact Sheet: Bladder Cancer
2. Krebs in Deutschland 2017/2018: Zentrum für Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland. e.V. (Hrsg.); Berlin, 2020
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020, AWMF-Registrierungsnummer 032/038OL. (<https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom>). Letzter Zugriff: 26.06.2022
4. TICE [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2020; (https://www.merck.com/product/usa/pi_circulars/t/tice_bcg/ticebcg_pi.pdf). Letzter Zugriff: 22.06.2022
5. Hemdan T et al. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon- α 2b in patients with T1 bladder cancer. *J Urol* 2014; 191: 1244–9
6. Herr HW et al. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. *Urol Oncol* 2015; 33: 108.e101–104
7. Anastasiadis A & de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. *Ther Adv Urol* 2012; 4: 13–32
8. Grimm MO et al. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". *Eur Urol* 2020; 78(5): 690–8
9. Harvey M et al. Critical shortage in BCG immunotherapy: How did we get here and where will it take us? *Urol Oncol* 2022; 40: 1–3
10. Mortezaei A et al. Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. *BJU Int* 2021; 127: 585–95
11. Maffezzini M et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. *Arch Ital Urol Androl* 2021; 93: 15–20
12. Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. *The Lancet Oncology* 2021; 22: 919–30

13. Tyson M et al. Safety, tolerability, and efficacy of tar-200 in patients with muscle-invasive bladder cancer who were unfit for curative intent therapy: a phase 1 trial. Annual Meeting of the Society of Urologic Oncology (SUO); 2021, Poster #173
14. Grimberg DC et al. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. *Eur Urol Focus* 2020; 6: 620–2
15. Heijden MSVD et al. SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy. *Journal of Clinical Oncology* 2022; 40: TPS593-TPS593
16. Wang H et al. TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma. *Journal of Clinical Oncology* 2022; 40: 4507
17. Babjuk M et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). *Eur Urol* 2022; 81: 7–94
18. Petrylak DP et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. *Journal of Clinical Oncology* 2022; 40: 435
19. Kaimakliotis HZ et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. *Journal of Clinical Oncology* 2020; 38: 5019
20. Szabados B et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. *Eur Urol* 2022; 82(2): 212–22
21. Necchi A et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *Eur Urol* 2020; 77: 439–46
22. Van Dorp J et al. LBA31 High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2). *Annals of Oncology* 2021; 32: S1305–S1306
23. Necchi A et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol* 2018; 36: 3353–60
24. Powles T et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). *J Clin Oncol* 2018; 36: 4506
25. Van der Heijden MS et al. Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). *Ann Oncol* 2019; 30: v358
26. Gao J et al. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). *J Clin Oncol* 2019; 37: 4551
27. Sonpavde G et al. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. *Future Oncol* 2020; 16: 4359–68
28. Powles T et al. A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). *J Clin Oncol* 2019; 37: TPS4592

29. Pfister C et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. *J Clin Oncol* 2022; 40: 2013–22
30. Bajorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med* 2021; 384: 2102–14
31. Fachinformation Opdivo® Stand: Mai 2022
32. Bellmunt J et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2021; 22: 525–37
33. Singh P et al. INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients. *J Clin Oncol* 2021; 39: 428
34. Joshi M et al. Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023. *J Clin Oncol* 2021; 39: 398
35. Fachinformation Bavencio; Stand: Februar 2022
36. Galsky MD et al. Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. *Cancer Research* 2021; 81: CT042
37. Powles T et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; 22: 931–45
38. Powles T et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2020; 21: 1574–88
39. Loriot Y et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2019; 381: 338–48
40. Powles TB et al. LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study. *Ann Oncol* 2021; 32: S1303
41. Mayr R et al. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. *Eur Urol* 2022; 81: 606–14
42. Powles T et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N Engl J Med* 2021; 384: 1125–35
43. Fachinformation Padcev™; Stand: April 2022
44. Diamantis N & Banerji U. Antibody-drug conjugates--an emerging class of cancer treatment. *Br J Cancer* 2016; 114: 362–7
45. Grivas P et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. *J Clin Oncol* 2022; 40: 434

46. Siefker-Radtke AO. Management of recurrent bladder cancer. August 2021; Clinical Care Options - Oncology. Available online: <https://www.clinicaloptions.com/oncology/programs/2021/uc-novel-therapies>
47. Cathomas R et al. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol 2022; 81: 95–103